Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Fig. 4

Microbiome composition and alpha diversity for non-responders before and after treatment. A Sample and group mean (π) relative abundances at the class level for classes comprising at least 3% relative abundance at one or more time points, denoted as before treatment (BL) and 7 and 30 days after last received RBX2660 treatment (7D, 30D). Class abbreviations refer to the taxonomic classes in Fig. 3. B Alpha diversity of non-responders for each time point group, expressed as the mean and standard deviation of the Shannon indices. There were no significant differences among the time points

Back to article page